B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy

Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commis

Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend i

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a B

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is cele

Acadia shares rise after CHMP recommends DAYBU for Rett syndrome in the European Union, reversing an

Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small

U.S. stocks slightly up, Dow Jones gains 0.1%. Health care shares jump 2.8%, ON Semiconductor down 2

Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m

-- European Commission decision expected in the coming months-- If approved, DAYBU® would become the

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Comm